Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Healthcare Biotechnology

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by lv_426on Nov 25, 2019 6:31pm

75 Views

Post# 30391169

RE:RE:RE:RE:RE:RE:RE:RE:RE:$1.00 - $4.00 Share Price in 6-12 months

Inv3strr wrote:
Yes now you understand. A very specific piece of equipment will bring in a substantial revenue stream.

and this very specific piece of equipment is a significant piece of revolutionary medical technology that serves a unserviced market.

Actually no I dont. What I do understand is that playing the "what if" is a waste of everyone's time. I think you should read the yearly "updates", then look to see how close they got one year on.

Bullboard Posts

Three micro-cap stocks on an upswing worth riding